EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Nanotechnology‐Assisted CAR ‐T‐Cell Therapy for Tumor Treatment

Yixin Wang, Allie Barrett, Quanyin Hu iD

WIREs Nanomedicine and Nanobiotechnology · 2024-09 · 16 (5)

DOI: 10.1002/wnan.2005 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift WIREs Nanomedicine and Nanobiotechnology, online erschienen am 19.10.2024. Verfasst von Yixin Wang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin, USA. Hauptthemen laut MEDLINE: Neoplasms, Immunotherapy, Adoptive, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 76 Literaturangaben. Gefördert von: American Cancer Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The adoptive transfer of T cells redirected by chimeric antigen receptors (CARs) has made a dramatic breakthrough in defeating hematological malignancies. However, in solid tumor treatment, CAR‐T‐cell therapy has attained limited therapeutic benefits due to insufficient infiltration and expansion, rapidly diminishing function following adoptive transfer, and severe life‐threatening toxicities. To address these challenges, advancements in nanotechnology have utilized innovative approaches to devise stronger CAR‐T cells with reduced toxicity and enhanced anti‐tumor activity. Equipping CAR‐T cells with multifunctional nanoparticles can abrogate immunosuppressive signaling in the tumor area, augment the functions of CAR‐T cells, and mitigate their toxicity against normal tissues. Additionally, nanoparticle‐mediated CAR‐T‐cell programming has the potential to optimize manufacturing and lower the cost for the broader implementation of CAR‐T‐cell therapy. In this review, we introduce the obstacles to be surmounted in CAR‐T‐cell therapy, highlight the nanotechnology‐based strategies that aim to enrich the therapeutic applications of CAR‐T‐cell therapy, and envision the prospect of nanoparticle‐assisted CAR‐T‐cell therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsImmunotherapy, AdoptiveReceptors, Chimeric AntigenHumansAnimalsT-LymphocytesNanotechnologyNanoparticlesMice

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Pharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin, USA.
  • Carbone Cancer Center, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA.
  • Wisconsin Center for NanoBioSystems, School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin, USA.

ORCID-Profile: Quanyin Hu

Förderung

  • American Cancer Society

Zitieren

APA

Wang, Y., Barrett, A., & Hu, Q. (2024). Nanotechnology‐Assisted CAR ‐T‐Cell Therapy for Tumor Treatment. WIREs Nanomedicine and Nanobiotechnology, 16(5). https://doi.org/10.1002/wnan.2005

Vancouver

Wang Y, Barrett A, Hu Q. Nanotechnology‐Assisted CAR ‐T‐Cell Therapy for Tumor Treatment. WIREs Nanomedicine and Nanobiotechnology. 2024;16(5). doi:10.1002/wnan.2005

BibTeX
@article{Wang2024,
  author = {Wang, Yixin and Barrett, Allie and Hu, Quanyin},
  title = {Nanotechnology‐Assisted CAR ‐T‐Cell Therapy for Tumor Treatment},
  journal = {WIREs Nanomedicine and Nanobiotechnology},
  year = {2024},
  volume = {16},
  number = {5},
  doi = {10.1002/wnan.2005}
}
Kostenlos starten →